Chapter 3 52 18. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. 19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213. 20. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–865. 21. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imagingdefined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–674. 22. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision inMRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241–248. 23. Yu X, Wang QX, Xiao WW, et al. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Cancer Commun (London, England). 2018;38:24. 24. Cercek A, GoodmanKA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12:513–519. 25. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–966. 26. Perez K, Safran H, Sikov W, et al. Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study. Am J Clin Oncol. 2017;40:283–287. 27. Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMAOncol.;4 . Epub aheadof print 2018. DOI: 10.1001/jamaoncol.2018.0071. 28. KustersM, BosmanS, vanZoggelD, et al. Local Recurrence in theLateral LymphNodeCompartment: ImprovedOutcomes with Induction Chemotherapy CombinedwithMultimodality Treatment. Ann Surg Oncol. 2016;23:1883–1889. 29. PelvExCollaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105:650–657. 30. Tanis PJ, Doeksen A, Van Lanschot JJB. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg. 2013;56:135. 31. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752–760. 32. Peng YF, Yu WD, Pan H Da, et al. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy. World J Gastroenterol. 2015;21:1851–1856. 33. Mace AG, Pai RK, Stocchi L, et al. American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58:32–44. 34. ManciniR, PattaroG,DiodoroMG, et al. TumorRegressionGradeAfterNeoadjuvantChemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up. Clin Colorectal Cancer. 2018;17:e13–e19.
RkJQdWJsaXNoZXIy MTk4NDMw